Mizuho Medy Co.,Ltd. (MIZUHO MEDY CO LTD) aksje

Mizuho Medy Co.,Ltd. engages in the research and development, manufacture, and sale of in vitro diagnostic products, and related scientific and technical information services in Japan. The company offers molecular diagnostic products, such as nucleic acid amplification test products comprising gene analysis instruments and mycoplasma pneumoniae nucleic acid kits. It also provides rapid immunoassay products, including influenza virus antigen test kit; RS virus and human metapneumovirus antigen test kit; streptococcus pneumoniae antigen and legionella antigen test kit; mycoplasma pneumoniae antigen test kit; adenovirus antigen test kit; rotavirus and adenovirus antigen test kit ;norovirus antigen test kit; Group A streptococcal antigen test kit; pregnancy test kit; ovulation test kit; and fecal occult blood test kit for in vitro diagnostic use. In addition, it offers reagents for detection in research and agriculture use; and reagents for biochemical test. Further, the company engages in import and export activities. It operates in the United States, Belgium, Finland, Netherlands, Taiwan, Thailand, and internationally. Mizuho Medy Co.,Ltd. was incorporated in 1977 and is headquartered in Tosu, Japan.